EuResist Network

A European multidisciplinary network for the fight of HIV drug resistance


Honors 2009 

 Winner of

The EuResist Integrated Database (EIDB) with data of more than 103.000 HIV patients is open for research studies.

Latest news

The Poster "Declining incidence of HIV multidrug resistance in Europe" has won the Best Poster Award at the 18th European AIDS Conference held Online & London, United Kingdom on October 27–30, 2021.


The project EuCARE breaks the news!


TG3 Lazio Region

Local/national TV news 


RCS Salute

health newspaper

"A Roma pronto un network di specialisti per capire il futuro del Covid-19 e per fronteggiare la quarta ondata"


La Tecnica della Scuola

school newspaper

"“La società è stata colpita dal COVID-19 sotto diversi aspetti: uno di questi, in gran parte sottovalutato, è la scuola. Per studiarla abbiamo coinvolto nel progetto anche gli studenti".

"Arruoleremo scuole in contesti socioeconomici diversi e valuteremo con un trial prospettico una metodologia di test salivare di gruppo, rapida ed economica"

Audible by Radio Radicale:

Derrick_blog_RadioRadicale-mp1132380Derrick Blog
00:00 / 02:33

Other news reports by:

EuCARE Kick-off meeting in Rome on 11-12 November 2021

We have been pleased to host in Rome the kick-off meeting of the project EuCARE European Cohorts of Patients and Schools to Advance Response to Epidemics funded by the EC under HORIZON-HLTH-2021-CORONA-01

Coordinated by Euresist Network, 22 primary universities, hospitals and ICT research centres are already working to provide robust, data driven evidence to deal with SARS-CoV-2 variants and COVID-19 epidemics. With the support of strong immuno-virological and artificial intelligence components, the study will take advantage of large hospital patients, vaccinated healthcare workers and schools’ cohorts in Europe, Kenya, Mexico, Russia and Vietnam to find an answer to urgent issues related to science and society. 

CARE HIV-TB-HCV: EU-Russia cooperation results
Online conference - June 15 2021, 9:00 – 16:00 CEST


The online meeting organised by the CARE Consortium had the objective to present and discuss outcomes and findings from CARE Common Action and other projects and initiatives in the frame of recent collaborative research in the WHO European Region.


It has seen the participation of CARE, ARREST-TB, CARE External Scientific Advisory Board, CARE External Ethics Review Board, Russian experts, NDPHS, Russian Ministry of Health, Russian Ministry of Science and Higher Education, EC, EU Delegation to the Russian Federation.


Download the Programme.​

Webinar "COVID-19 and variants: is it possible to re-open the schools?"

1st April 2021

The marginal role of schools as a center for spreading the infection, when the necessary containment measures are adopted, is now demonstrated by most of the scientific literature. However, doubts remain in society and in the political world, especially as regards high schools and relatively to the spread of viral variants.
On the contrary, the costs of closure are not yet fully known and are still likely to be underestimated.

The webinar sponsored by EuResist Network will support the scientific discussion on these themes while involving both the civil society and the political institutions.

With the participation of scientists as Antonella D'arminio Monforte, Sara Gandini, Daniele Novara, of associations as Save the Children, AcrionAid, ForumDD, of members of the Italian Parliament and of the Minister for Equal Opportunities and the Family Elena Bonetti.

Download the programme

Seminario 1° aprile  (7b).jpg

Relevant research results from the CARE project

The CARE TB diagnostics group has been looking into potential novel biomarkers of successful treatment of multidrug-resistant tuberculosis. With the support of Linear Mixed Models to analyse the change of metabolites in response to TB treatment in cohorts of patients from Russia and Lithuania, we identified and further evaluated at least 2 candidate urine biomarkers of response to treatment.


The CARE TB treatment management group has been progressing towards developing a Geno2Pheno TB tool for prediction of drug-resistance profiles of Mycobacterium tuberculosis (Mtb) from whole genome sequencing (WGS) data. We trained and evaluated a variety of RF-models on different genetic features for 9 important drugs using a set of up to 2,000 Mtb WGSs. The resulting models showed overall significantly improved performance compared to a state-of-the-art mutation catalogue, including both known resistance mediating and benign mutations.

The CARE HIV epidemiology and treatment resistance group has achieved important scientific progress in the evaluation of drug resistance to integrase strand inhibitors (INSTI). A new consensus A6 sequence has been created and also a full recombinant A6 viruse has been created which is now being tested against different drugs. A high-throughput sequencing assay for HIV-1 A6 strains has been established and validated on Swedish, German and Russian samples. The sub-subtype A6 has been analyzed for its in vitro phenotypic susceptibility to INSTIs and it showed to be as susceptible as the reference subtype B to INSTIs, including dolutegravir, bictegravir, cabotegravir. 


Furthermore, the CARE HIV/HCV and host genomics group has enrolled an extensive prospective cohort of over 6500 people with HIV and HIV/HCV coinfection in Georgia, Russia and Ukraine. Detailed clinical and demographical data have been collected from the region of the world where we have little data so far. An HIV cascade of care constructed for this cohort showed that the target of 90% PLHIV on ART was achieved in Georgia and Ukraine but not in Russia, and the target of 90% on those on ART having viral suppression was achieved only in Georgia. 

EuResist Network is an international non-profit partnership devoted to understanding and fighting the resistance to anti-HIV drugs.

Its approach is eminentely multidisciplinary and focused on exploiting the power of real world data at the benefit of the individual patient.

EuResist Network manages:


  1. the EuResist Integrated Data Base (EIDB), among the largest available databases of HIV genotypes and clinical response to antiretroviral therapy, with more than 96.000 patients. The EIDB is open for research studies.

  2. Reasearch projects on HIV and other infectious diseases.. EuResist Network is actively involved in front end research to combat HIV drug resistance and the spread of HIV and other infectious diseases. It coordinates and participates in several research projects, including EU funded projects.

  3. Training activities on HIV drug resistance and data management. EuResist Network organises on-site and distant courses and offers training material on drug resistance and drug resistance data management.

  4. The EuResist prediction engine, a data-driven system which predicts the response to combination drug therapy for a patient with a given viral genotype. The engine has an overall accuracy of around 77% which compares favourably with existing rules-based state-of-the-art systems such as HIVdb, ANRS, REGA.

  5. The EuResist Satellite DB (EsaDB), a tool for management of HIV patients data running locally on a PC. ESaDB is provided for free.

Ciao Andrea


On Feb 4th 2019, our great friend and EuResister Andrea De Luca lost his life in a horrible car accident, at the age of 55.

One year has passed and still we miss him with incredulity and sorrow. 
Among many other projects,  Andrea joined EuResist as a key leader soon after its launch, devoting his energy, commitment and capability to the success of the Network. He was an extra lively, smart, passionate, and positive person, always ready to help and take new tasks.
His loss is a huge loss for us, for his patients, for his beloved ones, for the international research community.

Ciao Andrea, we'll always miss you.


​CARE (Common Action against HIV/TB/HCV across the Regions of Europe) aims at analysing and addressing the human immunodeficiency virus (HIV), tuberculosis (TB) and hepatitis C (HCV) epidemics across Europe and Russia, by establishing new networks and consolidating previous cooperative actions between the European Union and the Russian Federation. 

Project coordinator F. Incardona (EuResist Network) Scientific coordinator J. Lundgren (CHIP/RegionH).

Funding received from the EU’s H2020 research and innovation programme under g.a N. 825673

If you want to contribute

please contact us:

Complete data instances

can be rewarded.

Find here the STANDARD DATUM defining the mandatory and preferable fields to be collected

An algorithm for Africa

​​​The INTEGRATE project aims at building and maintaining a large, curated collection of virological and clinical data to increase scientific knowledge on resistance to integrase strand transfer inhibitors (InSTI) and on the most appropriate use of this class of antiretroviral agents.

EuResist Network organises the EuResist Mentor School (EMS) an innovative educational project finalised to train young physicians and biologists in dealing with structured data (databases).

The EMS 2018 has been successfully held in Cologne 

EuResist has been supporting partner of the EDCTP networking action: "Integrated training activities and IT infrastructures to improve capacities in eastern African area"...

EuResist Network participates in the pilot project for the realization of a System of Health Monitoring and Surveillance activities in the Autonomous Region of Kurdistan...

EucoHIV is an independent self-constituted study group aiming at increasing scientific knowledge on HIV coreceptor usage and its clinical significance, including...

The CHAIN project aims at combat new and existing anti-HIV drug resistance in clinical settings, with a special emphasis on Eastern Europe and Africa... 

The EuResist Network is open to new partners of proved or potential scientific value for expanding both database and scientific programme. Co-operation with developing countries with high rates of HIV infections is mostly welcome.

All the partners have one representative in the EuResist Network Scientific Board. The Board evaluates requests to access the EIDB for scientific studies. Partner's activities and data are protected by the data and authorship policy.